Orion Oyj (OTCMKTS:ORINY) & SSP Group (OTCMKTS:SSPPF) Head-To-Head Contrast

Orion Oyj (OTCMKTS:ORINY) and SSP Group (OTCMKTS:SSPPF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Orion Oyj has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, SSP Group has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Earnings & Valuation

This table compares Orion Oyj and SSP Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orion Oyj	$1.29 billion	4.81	$234.64 million	$1.26	17.42
SSP Group	$4.35 billion	0.26	$9.94 million	N/A	N/A

Orion Oyj has higher earnings, but lower revenue than SSP Group.

Profitability

This table compares Orion Oyj and SSP Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion Oyj	23.01%	41.41%	22.43%
SSP Group	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Orion Oyj and SSP Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion Oyj	0	0	0	0	0.00
SSP Group	0	1	0	2	3.33

Summary

Orion Oyj beats SSP Group on 5 of the 9 factors compared between the two stocks.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

About SSP Group

SSP Group plc operates food and beverage outlets in North America, Europe, the United Kingdom, Ireland, the Asia Pacific, Eastern Europe, the Middle East, and internationally. The company operates outlets at airports, railway stations, motorway service areas, hospitals, and shopping centers. It also operates sandwich shops, cafes, bars, and restaurants. SSP Group plc was founded in 1961 and is headquartered in London, the United Kingdom.